EZH2 and B-cell non-Hodgkin lymphoma: Finally, CPI-1205 selectively inhibits the interaction of EZH2 with PRC2 complex and is currently evaluated in a phase 1 clinical trial in patients with B-cell lymphomas (NCT02395601).